Skip to main content
Premium Trial:

Request an Annual Quote

The Silly and the Serious

"Cheap DNA sequencing: what's in it for you?" asks Amanda Wills at Mashable Tech. She goes on to discuss a variety of commercially available DNA screening services as well as how genome sequencing has helped patients with cancers and rare diseases in the clinical setting.

Massachusetts General Hospital's Daniel MacArthur tells Wills that while personal genome sequencing is still prohibitively costly for most people, it is becoming more affordable every day. Wills reports: "When commercialization eventually drives down the price, DNA sequencing could even be a project your kids do in science class, MacArthur suggests."

Speaking about 23andMe's testing service, which screens for disease risk as well as some other, apparently benign phenotypic traits — sneeze reflex in sunlight, for example — MacArthur tells Mashable that, "for some people, these non-medical aspects end up proving much more interesting than their disease predictions." Still, he adds, "this isn't just for fun — for people who already have serious diseases, DNA sequencing can profoundly change their diagnosis and treatment."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.